DRI Healthcare Trust (DHTRF) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of DRI Healthcare Trust stock $23.38, price $13.52, upside +72.9%, quality 43 out of 100. Rating: strongly undervalued. Calculated from audited financials with 6 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
35‑month range $7.20 – $13.52 · fair‑value band $12.72 – $41.44 · the $13.52 price screens below the $23.38 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow DRI Healthcare Trust in your weekly email
Every Wednesday you see whether DRI Healthcare Trust is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas.
Show moreShow less
The company was incorporated in 2020 and is headquartered in Toronto, Canada.
Stock analysis
DRI Healthcare Trust (DHTRF) currently trades at $13.52, while our model-based Fair Value estimate is $23.38, implying the stock looks roughly 42% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of $17.47 per share, and 3 of the 5 models we run sit above the $13.52 price.
Bear case: the DCF Models group reads lowest at $14.12, and 2 of the 5 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $12.72 (bear) to $41.44 (bull), the price of $13.52 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
DRI Healthcare Trust reported revenue of $153M in FY2025 versus $73.3M in FY2021, a compound +20.3%/yr. Reported net income was −$50.5M in FY2025.
Key figures
Market cap $743M Small · P/S ratio 3.45 · EPS (TTM) $−0.8100 · Dividend yield 3.1% · Net margin −22.0% · Return on equity −9.4% · Return on assets 4.4% · Operating margin 34.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 33 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and 27% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 73%, DHTRF screens cheaper than that median.
Fair Value models
Bear$12.72Fair Value $23.38Bull$41.44
Price $13.52 · Upside +72.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.61/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+9.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.3%
’21
’22
’23
’24
’25
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes about as much growth as the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+19.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+15.9%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +16.7% a year for the price and +13.2% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 5/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score43 · Bottom 25%
Fair Value upside+72.9% · Top 25%
Profitability
Return on assets−5.4% · Bottom 25%
Net margin (12 months)−22.0% · Bottom 25%
Operating margin (12 months)34.7% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)7.5% · Above median
Dividend yield (12 months)3.1% · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/B1.69× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months)3.70× · Pricier than median
Price / free cash flow (fiscal year)33.8× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is DRI Healthcare Trust (DHTRF) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of $23.38 versus a price of $13.52, about +73% upside (undervalued).
What is the fair value of DHTRF?
Our model-based fair value for DRI Healthcare Trust is $23.38 (as of Nov 7, 2026), built from audited fundamentals. The current price: $13.52.
What is the quality score of DHTRF?
DRI Healthcare Trust has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DRI Healthcare Trust (DHTRF)?
Our model-based price target is the fair value of $23.38 (as of Nov 7, 2026) from 6 valuation models. Cautious scenario $12.72, optimistic scenario $41.44. It is a calculation from audited fundamentals, not an analyst target.
What is the DRI Healthcare Trust stock forecast for 2026?
Our models put fair value at $23.38, about +73% upside versus a price of $13.52 (undervalued). Cautious scenario $12.72, optimistic scenario $41.44. The calculation is refreshed regularly with new filings.
What is the revenue of DRI Healthcare Trust (DHTRF)?
DRI Healthcare Trust reported trailing-twelve-month revenue of about $201M (latest available figure, as of Nov 7, 2026).
Does DRI Healthcare Trust pay a dividend?
DRI Healthcare Trust currently shows a dividend yield of 3.11% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of DRI Healthcare Trust (DHTRF) and when is the ex-dividend date?
DRI Healthcare Trust pays a dividend of $0.42 per share a year, a dividend yield of 3.1%. The last ex-dividend date was Sep 29, 2026. Free cash flow covers the dividend 0.95 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into DRI Healthcare Trust (DHTRF)?
For today's price to be fair in a discounted-cash-flow model, DRI Healthcare Trust would have to grow free cash flow by +19.5 % per year for five years (discount rate 10.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +20.3 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of DHTRF use?
Our models discount DRI Healthcare Trust at 10.2 %: a base by market capitalisation (small), damped by beta 0.62, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For DRI Healthcare Trust that is +19.5 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.2 %) and the same formula as our fair value.
How much growth has DRI Healthcare Trust (DHTRF) delivered so far?
Over the past 4 years revenue at DRI Healthcare Trust grew +20.3 % a year. The price currently implies free-cash-flow growth of +19.5 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of DRI Healthcare Trust (DHTRF) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into DRI Healthcare Trust (+19.5 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of DRI Healthcare Trust (DHTRF)?
The free-cash-flow yield on the price is 2.96 %: that much free cash flow DRI Healthcare Trust produces per unit of market value. When it exceeds the discount rate of our models (10.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of DRI Healthcare Trust (DHTRF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DRI Healthcare Trust it is $23.38 per share (as of Nov 7, 2026), against a price of $13.52. It is the blended result of 6 valuation models in 3 families (DCF Models, Multiples, Growth DCF).
Is DRI Healthcare Trust stock overvalued or undervalued in 2026?
As of Nov 7, 2026, DHTRF trades below its calculated fair value: price $13.52, fair value $23.38, a gap of about +73% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DHTRF?
No. The price is what the market pays today ($13.52); the fair value is what the company's own numbers justify ($23.38). For DRI Healthcare Trust the two are $9.86 per share apart. That gap is exactly why we show both numbers side by side.
How much is DRI Healthcare Trust worth?
The market values DRI Healthcare Trust at about $743M (market capitalisation, as of Nov 7, 2026). Per share that is $13.52; our models calculate a fair value of $23.38 per share.
What do the bullish and bearish scenarios say about DHTRF?
Our models span a range for DRI Healthcare Trust: cautious scenario $12.72, base $23.38, optimistic $41.44 per share (as of Nov 7, 2026, price $13.52). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of DRI Healthcare Trust (DHTRF)?
Balance-sheet figures for DRI Healthcare Trust (as of Nov 7, 2026): return on equity −9.4%. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is DHTRF from its 52-week high?
DRI Healthcare Trust trades at $13.52, at its 52-week high of $13.52 and 27% above the low of $10.64 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $23.38 is for.
Which stocks are comparable to DRI Healthcare Trust?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DRI Healthcare Trust stock attractive at the current price?
The data as of Nov 7, 2026: price $13.52, calculated fair value $23.38 (+73%), Quality Score 43/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DHTRF calculated?
We run DRI Healthcare Trust through 6 models from 3 families: DCF Models, Multiples, Growth DCF. Every model gets the same audited fundamentals; the fair value of $23.38 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. DRI Healthcare Trust currently trades 42% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DRI Healthcare Trust (DHTRF)?
The closing price on Nov 6, 2026 was $13.52. Our model-based fair value is $23.38, about +73% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DRI Healthcare Trust right now?
The large discount to fair value meets weak quality (43/100). That raises the risk this is a value trap rather than a bargain. The model range is unusually wide ($12.72 to $41.44). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Key figures of DRI Healthcare Trust
How large is the market capitalisation of DRI Healthcare Trust (DHTRF)?
The market capitalisation of DRI Healthcare Trust is $743M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of DRI Healthcare Trust (DHTRF)?
The price-to-sales ratio of DRI Healthcare Trust is 3.45 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of DRI Healthcare Trust (DHTRF)?
Earnings per share at DRI Healthcare Trust are $−0.8100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of DRI Healthcare Trust (DHTRF)?
The dividend yield of DRI Healthcare Trust is 3.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of DRI Healthcare Trust (DHTRF)?
The net margin of DRI Healthcare Trust is −22.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of DRI Healthcare Trust (DHTRF)?
The return on equity (ROE) of DRI Healthcare Trust is −9.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the return on assets of DRI Healthcare Trust (DHTRF)?
The return on assets (ROA) of DRI Healthcare Trust is 4.4% (last twelve months). Profit relative to everything the company owns. Harder to inflate than return on equity because debt does not boost it.
What is the operating margin of DRI Healthcare Trust (DHTRF)?
The operating margin of DRI Healthcare Trust is 34.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at DRI Healthcare Trust (DHTRF)?
Revenue at DRI Healthcare Trust is growing +7.5% versus a year earlier (3y avg +24.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at DRI Healthcare Trust (DHTRF)?
Earnings per share at DRI Healthcare Trust are growing +15.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does DRI Healthcare Trust (DHTRF) carry?
The net debt of DRI Healthcare Trust is $334M (fiscal year 2025, ≈ 15.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch DRI Healthcare Trust in the live analysis
One click puts DRI Healthcare Trust on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 7, 2026